UnityPoint Health Ventures

UnityPoint Health Ventures, established in 2019, serves as the corporate venture capital arm of UnityPoint Health, located in West Des Moines, Iowa. The organization is dedicated to investing in early-stage companies within various sectors, including healthcare, digital therapeutics, information technology, tech-enabled services, medical devices, and diagnostics. Its Innovation Venture Fund focuses on identifying financial and strategic investment opportunities that enhance the patient and provider experience. By partnering with innovative ideas and companies, UnityPoint Health Ventures aims to contribute to advancements in the healthcare landscape.

Austin Duke

Venture Investing Director

Erin Templeton

Innovation Associate

Anthony Zlaket

Venture Associate

Past deals in Iowa

VIDA

Series C in 2020
VIDA Diagnostics, Inc. specializes in clinical imaging software and analysis services, focusing on lung and respiratory care. The company's flagship products include LungPrint, an automated AI-powered tool that analyzes chest CT scans to assess lung physiology and functional tissue, and VIDA|precision, which provides detailed lung measurements for pulmonary clinicians. Additionally, VIDA|vision enables interactive examination of advanced quantitative imaging analysis results. The company offers comprehensive image analysis services for both academic and clinical trials, including study design, CT protocol development, and data analysis. Founded in 2004 and headquartered in Coralville, Iowa, with an office in Minneapolis, VIDA's software is FDA cleared and CE-marked, making it suitable for clinical use in multiple regions, including the US, European Economic Area, Canada, and Australia. Through its innovative solutions, VIDA aims to empower healthcare organizations and physicians to enhance patient outcomes, especially for those at risk of chronic respiratory diseases such as COPD, interstitial lung disease, lung cancer, and COVID-19.

VIDA

Corporate Round in 2019
VIDA Diagnostics, Inc. specializes in clinical imaging software and analysis services, focusing on lung and respiratory care. The company's flagship products include LungPrint, an automated AI-powered tool that analyzes chest CT scans to assess lung physiology and functional tissue, and VIDA|precision, which provides detailed lung measurements for pulmonary clinicians. Additionally, VIDA|vision enables interactive examination of advanced quantitative imaging analysis results. The company offers comprehensive image analysis services for both academic and clinical trials, including study design, CT protocol development, and data analysis. Founded in 2004 and headquartered in Coralville, Iowa, with an office in Minneapolis, VIDA's software is FDA cleared and CE-marked, making it suitable for clinical use in multiple regions, including the US, European Economic Area, Canada, and Australia. Through its innovative solutions, VIDA aims to empower healthcare organizations and physicians to enhance patient outcomes, especially for those at risk of chronic respiratory diseases such as COPD, interstitial lung disease, lung cancer, and COVID-19.